[Chairman and CEO of Biostar Pharmaceuticals,opts 10b5-1 Share Repurchase Plan Rule 10b5-1 permitsrporate officers, directors and others toopt written, pre-arranged stock trading plans when they are not in possession of material, non-public information. These planslow insiders to have shares bought or sold for their accounts over a period of time regardless of any material, non-public]
[FORM 10-K /A Amendment No. 1 (Mark One) x December 31, 2010 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code)] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161598) of Biostar Pharmaceuticals, Inc. of our report dated March 24, 2011 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K of] [CERTIFICATION I, Ronghua Wang, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION I, Zack Pan, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]
[FORM 10-K /A Amendment No. 1 (Mark One) x December 31, 2010 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code)] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161598) of Biostar Pharmaceuticals, Inc. of our report dated March 24, 2011 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K of] [CERTIFICATION I, Ronghua Wang, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION I, Zack Pan, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]
[FORM 10-K /A Amendment No. 1 (Mark One) x December 31, 2010 For the fiscal year ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to theorporation by reference in the Registration Statement on Form S-8 (No. 333-161598) of Biostar Pharmaceuticals, of our reportted March 24, 2011 relating to thensolidated financial statements, which appears in the Annual Report on Form 10-K of Biostar] [CERTIFICATION I, Ronghua Wang, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Zack Pan, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 6 EX-32.2]
[FORM 10-K /A Amendment No. 1 (Mark One) x December 31, 2010 For the fiscal year ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to theorporation by reference in the Registration Statement on Form S-8 (No. 333-161598) of Biostar Pharmaceuticals, of our reportted March 24, 2011 relating to thensolidated financial statements, which appears in the Annual Report on Form 10-K of Biostar] [CERTIFICATION I, Ronghua Wang, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Zack Pan, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 6 EX-32.2]
[Biostar Pharmaceuticals, Inc. Reports First Quarter 2011 Results; Revenues Increase 24% to $15.3 Million with Adjusted EPS of $0.11 XIANYANG, China, May 16, 2011 -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing Capsules"), and a variety of pharmaceutical products, today announced]
[Biostar Pharmaceuticals, Inc. Reports First Quarter 2011 Results; Revenues Increase 24% to $15.3 Million with Adjusted EPS of $0.11 XIANYANG, China, May 16, 2011 -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing Capsules"), and a variety of pharmaceutical products, today announced]
[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT W I T N E S S E T H: WHEREAS WHEREAS NOW, THEREFORE 1. Employment of Chief Financial Officer of the Company . 2. Term 3. Duties . 1 4. Compensation . a. (i) Executive shall be paid a base pay of USD 10,000 per month during the term, payable on the last day] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. EX-32.2 6 ex32-2.htm]
[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT W I T N E S S E T H: WHEREAS WHEREAS NOW, THEREFORE 1. Employment of Chief Financial Officer of the Company . 2. Term 3. Duties . 1 4. Compensation . a. (i) Executive shall be paid a base pay of USD 10,000 per month during the term, payable on the last day] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. EX-32.2 6 ex32-2.htm]
[Biostar Pharmaceuticals, Reports First Quarter 2011 Results; Revenuesrease 24% to $15.3 Million withjusted EPS of $0.11 XIANYANG, China, May 16, 2011 -- Biostar Pharmaceuticals, (Nasdaq: BSPM) ("Biostar" or "thempany"), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acidpsules ("Xin Aoxingpsules"), and a variety of pharmaceutical products, today announced financial results for]
